ATE479689T1 - Mehrfach wirkende antiangiogene und zytotoxische verbindungen und verfahren zu ihrer verwendung - Google Patents

Mehrfach wirkende antiangiogene und zytotoxische verbindungen und verfahren zu ihrer verwendung

Info

Publication number
ATE479689T1
ATE479689T1 AT02801736T AT02801736T ATE479689T1 AT E479689 T1 ATE479689 T1 AT E479689T1 AT 02801736 T AT02801736 T AT 02801736T AT 02801736 T AT02801736 T AT 02801736T AT E479689 T1 ATE479689 T1 AT E479689T1
Authority
AT
Austria
Prior art keywords
methods
compounds
antiangiogic
acting
cytotoxic compounds
Prior art date
Application number
AT02801736T
Other languages
English (en)
Inventor
Aleem Gangjee
Original Assignee
Univ Holy Ghost Duquesne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Holy Ghost Duquesne filed Critical Univ Holy Ghost Duquesne
Application granted granted Critical
Publication of ATE479689T1 publication Critical patent/ATE479689T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT02801736T 2001-10-18 2002-10-16 Mehrfach wirkende antiangiogene und zytotoxische verbindungen und verfahren zu ihrer verwendung ATE479689T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/982,351 US6770652B2 (en) 2001-10-18 2001-10-18 Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
PCT/US2002/032963 WO2003032911A2 (en) 2001-10-18 2002-10-16 Anti-angiogenic and cytotoxic fused pyrimidines

Publications (1)

Publication Number Publication Date
ATE479689T1 true ATE479689T1 (de) 2010-09-15

Family

ID=25529077

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02801736T ATE479689T1 (de) 2001-10-18 2002-10-16 Mehrfach wirkende antiangiogene und zytotoxische verbindungen und verfahren zu ihrer verwendung

Country Status (7)

Country Link
US (1) US6770652B2 (de)
EP (1) EP1469809B1 (de)
AT (1) ATE479689T1 (de)
AU (1) AU2002335035A1 (de)
CA (2) CA2722197C (de)
DE (1) DE60237546D1 (de)
WO (1) WO2003032911A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030319B2 (en) 2005-02-10 2011-10-04 Duquesne University Of The Holy Ghost Methods for treating cancer and other pathological proliferating disorders by inhibiting mitosis using pyrrolo[2 3-d]pyrimidines
US8071609B2 (en) * 2005-08-11 2011-12-06 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
EP2300013B2 (de) 2008-05-21 2024-11-13 Takeda Pharmaceutical Company Limited Phosphor-derivate als kinase-inhibitoren
JP2012511575A (ja) 2008-12-12 2012-05-24 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのアザインドール誘導体
EP2704572B1 (de) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Verfahren zur hemmung der zellproliferation bei efgr-vermitteltem krebs
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
IL286839B (en) * 2016-02-19 2022-08-01 Pmv Pharmaceuticals Inc Propyne-indole compounds
KR102133569B1 (ko) * 2018-06-28 2020-07-13 한국과학기술연구원 신규한 피롤로[2,3-d]피리미딘-4-온 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
SMT202500339T1 (it) 2019-09-23 2025-11-10 Pmv Pharmaceuticals Inc Metodi e composti per ripristinare la funzione di p53 mutante
US12570645B2 (en) 2020-06-22 2026-03-10 Pmv Pharmaceuticals, Inc. Uses of p53 x-ray co-crystal structures
WO2021262484A1 (en) 2020-06-24 2021-12-30 Pmv Pharmaceuticals, Inc. Combination therapy for treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0438261A3 (en) * 1990-01-16 1992-02-26 Takeda Chemical Industries, Ltd. Condensed heterocyclic glutamic acid derivatives, their production and use
US5939420A (en) * 1991-04-08 1999-08-17 Duquesne University Of The Holy Ghost Pyrrolo 2,3d!derivatives
US5877178A (en) * 1991-04-08 1999-03-02 Duquesne University Of The Holy Ghost Pyrimidine derivatives and methods of making and using these derivatives
US5502187A (en) * 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
DE59500788D1 (de) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
JP4145955B2 (ja) * 1994-09-29 2008-09-03 ノバルティス アクチェンゲゼルシャフト ピロロ〔２，３−ｄ〕ピリミジン及びその使用
US6562969B1 (en) * 1996-12-24 2003-05-13 Research Development Foundation Ricin inhibitors and methods for use thereof
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6187177B1 (en) * 1999-03-12 2001-02-13 Scott E. Ogburn Industrial filter
WO2002016326A1 (en) * 2000-08-18 2002-02-28 Agouron Pharmaceuticals, Inc. Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases
EP1463742A4 (de) * 2001-06-21 2006-05-10 Ariad Pharma Inc Neue pyrazolo- und pyrrolo-pyrimidine und ihre verwendungszwecke

Also Published As

Publication number Publication date
EP1469809A4 (de) 2005-11-09
DE60237546D1 (de) 2010-10-14
US6770652B2 (en) 2004-08-03
CA2722197C (en) 2015-12-29
EP1469809B1 (de) 2010-09-01
CA2481560C (en) 2011-02-01
AU2002335035A1 (en) 2003-04-28
CA2481560A1 (en) 2003-04-24
CA2722197A1 (en) 2003-04-24
US20030181467A1 (en) 2003-09-25
WO2003032911A3 (en) 2003-07-31
EP1469809A2 (de) 2004-10-27
WO2003032911A2 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
NZ517758A (en) Pyrazolopyrimidines useful as therapeutic agents
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
MXPA04004220A (es) Derivados de quinazolina como agentes antitumorales.
MX337817B (es) Pirazolo [1,5-a] pirimidinas de utilidad como inhibidores de proteina quinasas.
MXPA04004219A (es) Derivados de quinazolina como agentes antitumorales.
MY138851A (en) Quinazoline derivatives
MY134848A (en) Pyrrolo[2,1-f] [1,2,4] triazine inhibitors of kinases
UA89038C2 (en) Pyrrolotriazine compounds as kinase inhibitors
MY147628A (en) Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
MY146474A (en) Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
SG132683A1 (en) Imidazopyrazine tyrosine kinase inhibitors
MY158054A (en) 4-anilino quinazoline derivatives as antiproliferative agents
JO2503B1 (en) Benzathiazole derivatives
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
TW200602328A (en) Quinazoline derivatives
WO2006084017A3 (en) Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
CY1112400T1 (el) Παραγωγα πυραζολοπυριμιδινης ως αναστολεις της εξαρτωμενης απο κυκλινη κινασης
MXPA06003161A (es) Derivados de quinazolina.
DE60237546D1 (de) Mehrfach wirkende antiangiogene und zytotoxische verbindungen und verfahren zu ihrer verwendung
UA83091C2 (en) Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
ZA200702645B (en) Diaminotriazole compounds useful as protein kinase inhibitors
CY1110666T1 (el) Πυραζολοπυριμιδινες καταλληλες για θεραπεια καρκινικων νοσων
WO2002028861A3 (en) Methods and compounds for treating proliferative diseases
AU2972701A (en) 3-aminopyrazole inhibitors of cyclin dependent kinases

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties